Incretin-based therapies in type 2 diabetes: A review of clinical results

Research output: Contribution to journalArticlepeer-review


GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
Issue numberSUPPL. 2
Publication statusPublished - Dec 15 2008


  • Diabetes mellitus
  • DPP-4 inhibitors
  • Exenatide
  • GLP-1 analogues
  • Sitagliptin
  • Vidagliptin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology


Dive into the research topics of 'Incretin-based therapies in type 2 diabetes: A review of clinical results'. Together they form a unique fingerprint.

Cite this